Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-15

Clinical Trial Update: A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating abemaciclib in combination with hormone therapy for early breast cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasms | Phase 3 | Status: TERMINATED | Results posted: 2025-07-15